Tetsuya Hosooka, MD, PhD
Education
1994: M.D. in Tokushima University School of Medicine.
2002: Ph.D. in Kobe University Graduate School of Medicine.
Employment
2021-Present: Associate Professor, Department of Nutrition and Life Sciences,
School of Food and Nutritional Sciences, and Graduate School of Integrated
Pharmaceutical and Nutritional Sciences, University of Shizuoka.
2021-Present: Visiting Associate Professor, Division of Diabetes andEndocrinology, Kobe University Graduate School of Medicine.
2019-2021: Associate Professor, Division of Development of Advanced
Therapy for Metabolic Disease, Kobe University Graduate School of Medicine.
2010-2019: Assistant Professor, Division of Diabetes and Endocrinology, Kobe
University Graduate School of Medicine.
2008-2010: Postdoctoral Fellow, Division of Endocrinology, Diabetes, andMetabolism, Department of Medicine, Beth Israel Deaconess Medical Center,Harvard Medical School.
2007: COE Postdoctoral Fellow, Division of Diabetes and Endocrinology, Kobe
University Graduate School of Medicine.
2002-2007: Postdoctoral Fellow, Division of Diabetes and Endocrinology, Kobe
University Graduate School of Medicine.
1994-1998: Resident, Kobe Medical Center, Kobe Rosai Hospital, and Suma
Red Cross Hospital.
Publications (2014-Present)
1. Imamori M*, Hosooka T*† (*co-first author, †corresponding author), Imi
Y, Hosokawa Y, Yamaguchi K, Itoh Y, Ogawa W. Thrombospondin-1
promotes liver fibrosis by enhancing TGF-β action in hepatic stellate cells.
Biochem Biophys Res Commun. 693: 149369, 2024.
2. EMPA-KIDNEY Collaborative Group. Effects of empagliflozin on
progression of chronic kidney disease: a prespecified secondary analysis

from the empa-kidney trial. Lancet Diabetes Endocrinol. 12: 39-50, 2024.
3. EMPA-KIDNEY Collaborative Group. Impact of primary kidney diseaseon the effects of empagliflozin in patients with chronic kidney disease:secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes
Endocrinol. 12: 51-60, 2024.
4. Kasahara N, Imi Y, Amano R, Shinohara M, Okada K, Hosokawa Y,Imamori M, Tomimoto C, Kunisawa J, Kishino S, Ogawa J, Ogawa W,
Hosooka T (corresponding author). A gut microbial metabolite of linoleic
acid ameliorates liver fibrosis by inhibiting TGF-β signaling in hepatic
stellate cells. Sci Rep. 13: 18983, 2023.
5. Ikuta K, Hayashi S, Kikuchi K, Fujita M, Anjiki K, Onoi Y, Tachibana S,Suda Y, Wada K, Kuroda Y, Nakano N, Maeda T, Matsumoto T, Hosooka
T, Ogawa W, Kuroda R. Osteoarthritis Cartilage. S1063-4584(23)00893-2,2023.
6. Imi Y, Amano R, Kasahara N, Obana Y, Hosooka T (corresponding author).
Nicotinamide mononucleotide induces lipolysis by regulating ATGL
expression via the SIRT1-AMPK axis in adipocytes. Biochem Biophys Rep.
34: 101476, 2023.
7. Hosokawa Y, Hosooka T (corresponding author), Imamori M, Yamaguchi
K, Itoh Y, Ogawa W. Adipose tissue insulin resistance exacerbates liver
inflammation and fibrosis in a diet-induced NASH model. HepatolCommun, 7: e0161, 2023.
8. Imi Y, Amano R, Kasahara N, Obana Y, Hosooka T (corresponding author).
Nicotinamide mononucleotide induces lipolysis by regulating ATGL
expression via the SIRT1-AMPK axis in adipocytes. Biochem Biophys Rep.
34: 101476, 2023.
9. Kanagaki S, Tsutsui Y, Kobayashi N, Komine T, Ito M, Akasaka Y,Nagasawa M, Ide T, Omae N, Nakao K, Rembutsu M, Iwago M, Yonezawa
A, Hosokawa Y, Hosooka T, Ogawa W, Murakami K. Activation of AMPactivated protein kinase (AMPK) by a small-molecule compound thatinhibits AMPK interaction with prohibitins. iScience, 26: 106293, 2023.

10. The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N,Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne
KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K,Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T,Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, GotoS, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J,Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in
Patients with Chronic Kidney Disease. N Engl J Med. 388: 117-127, 2023.
11. Imi Y, Ogawa W, Hosooka T (corresponding author). Insulin resistance inadipose tissue and metabolic diseases. Diabetol Int. 14: 119-124, 2023.
12. Hirata Y, Nomura K, Kato D, Tachibana Y, Niikura T, Uchiyama K,Hosooka T, Fukui T, Oe K, Kuroda R, Hara Y, Adachi T, Shibasaki K,Wake H, Ogawa W. A Piezo1–KLF15–IL-6 axis mediates immobilizationinduced muscle atrophy. J Clin Invest. 132: 1-13, 2022.
13. Yoshida N, Yamashita T, Osone T, Hosooka T, Shinohara M, Kitahama S,
Sasaki K, Sasaki D, Yoneshiro T, Suzuki T, Emoto T, Saito Y, Ozawa G,Hirota Y, Kitaura Y, Shimomura Y, Okamatsu-Ogura Y, Saito M, Kondo
A, Kajimura S, Inagaki T, Ogawa W, Yamada T, Hirata KI. Bacteroides
spp. promotes branched-chain amino acid catabolism in brown fat andinhibits obesity. iScience, 24: 103342, 2021.
14. Yoshino K, Hosooka T (co-first and corresponding author), Shinohara M,Aokia C, Hosokawa Y, Imamori M, Ogawa W. Canagliflozin ameliorates
hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2.
Biochemical and Biophysical Research Communications. 557: 62-68, 2021.
15. Kuramoto N, Nomura K, Kohno D, Kitamura T, Karsenty G, Hosooka T,Ogawa W. Role of PDK1 in skeletal muscle hypertrophy induced bymechanical load. Sci Rep. 11: 3447, 2021.
16. Nabatame Y, Hosooka T (co-first author), Aoki C, Hosokawa Y, Imamori
M, Tamori Y, Okamatsu-Ogura Y, Yoneshiro T, Kajimura S, Saito M,Ogawa W. Kruppel-like factor 15 regulates fuel switching between glucose
and fatty acids in brown adipocytes. J Diabetes Investig. 12: 1144-1151,

2021.
17. Hosooka T, Hosokawa Y, Matsugi K, Shinohara M, Senga Y, Tamori Y,Aoki C, Matsui S, Sasaki T, Kitamura T, Kuroda M, Sakaue H, Nomura
K, Yoshino K, Nabatame Y, Itoh Y, Yamaguchi K, Hayashi Y, Nakae J,Accili D, Yokomizo T, Seino S, Kasuga M, Ogawa W. The PDK1-FoxO1signaling in adipocytes controls systemic insulin sensitivity through the
5-lipoxygenase-leukotriene B4 axis. Proc Natl Acad Sci U S A. 117: 1167411684, 2020.
18. Hirata Y, Nomura K, Senga Y, Okada Y, Kobayashi K, Okamoto S,
Minokoshi Y, Imamura M, Takeda S,

Hosooka T, Ogawa W.

Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis.
JCI Insight. 4: e124952, 2019.
19. Mizusaki N, Nomura K, Hosooka T, Shiomi M, Ogawa K, Tsunoda T,Tamori Y, Ogawa W. The Novel Lipid-Lowering Drug D-47 Ameliorates
Hepatic Steatosis and Promotes Brown/Beige-Like Change of White
Adipose Tissue in db/db Mice. Kobe J Med Sci. 65: E36-E43, 2019.
20. Okada K, Hosooka T, Shinohara M, Ogawa W. Modulation of lipid
mediator profile may contribute to amelioration of chronic inflammationin adipose tissue of obese mice by pioglitazone. Biochem Biophys ResCommun. 505: 29-35, 2018.
21. Matsugi K, Hosooka T, Nomura K, Ogawa W. Thrombospondin 1
suppresses insulin signaling in C2C12 myotubes. Kobe J. Med. Sci. 62:E13-8, 2016.
22. Hosooka T, Ogawa W. A novel role for the cell cycle regulatory complex
cyclin D1-CDK4 in gluconeogenesis. J Diabetes Invest. 7: 27-8, 2016.
23. Ijuin T, Hosooka T, Takenawa T. Phosphatidylinositol 3,4,5-trisphosphate
phosphatase SKIP links endoplasmic reticulum stress in skeletal muscle
to insulin resistance. Mol Cell Biol. 36: 108-18, 2015.
24. Asahara S, Etoh H, Inoue H, Teruyama K, Shibutani Y, Ihara Y, Kawada
Y, Bartolome A, Hashimoto N, Matsuda T, Koyanagi-Kimura M, Kanno A,Hirota Y, Hosooka T, Nagashima K, Nishimura W, Inoue H, Matsumoto
M, Higgins MJ, Yasuda K, Inagaki N, Seino S, Kasuga M, Kido Y. Paternalallelic mutation at the Kcnq1 locus reduces pancreatic β-cell mass by
epigenetic modification of Cdkn1c. Proc Natl Acad Sci U S A. 112: 8332-7,
2015.
25. Kraus BJ, Sartoretto JL, Polak P, Hosooka T, Shiroto T, Eskurza I, LeeSA, Jiang H, Michel T, Kahn BB. Novel role for retinol-binding protein 4in the regulation of blood pressure. FASEB J. 29: 3133-40, 2015.
26. Takenaka N, Sumi Y, Matsuda K, Fujita J, Hosooka T, Noguchi T, Aiba A,Satoh T. Role for RalA downstream of Rac1 in skeletal muscle insulin
signalling. Biochem J. 469: 445-54, 2015.
27. Ijuin T, Hatano N, Hosooka T, Takenawa T. Regulation of insulin
signaling in skeletal muscle by PIP3 phosphatase, SKIP, and endoplasmic
reticulum molecular chaperone glucose-regulated protein 78. Biochim
Biophys Acta. 1853: 3192-201, 2015.
28. Takenaka N, Yasuda N, Nihata Y, Hosooka T, Noguchi T, Aiba A, Satoh T.
Role of the guanine nucleotide exchange factor in Akt2-mediated plasma
membrane translocation of GLUT4 in insulin-stimulated skeletal muscle.
Cell Signal. 26: 2460-9, 2014.
29. Takenaka N, Izawa R, Wu J, Kitagawa K, Nihata Y, Hosooka T, NoguchiT, Ogawa W, Aiba A, Satoh T. A critical role of the small GTPase Rac1 in
Akt2-mediated GLUT4 translocation in mouse skeletal muscle. FEBS J.
281: 1493-504, 2014.